Search the GHTC website

Global health R&D delivers for Rhode Island

US government investment in global health R&D has delivered

$23.9 million
to Rhode Island research institutions
250+ new jobs
for Rhode Island
Global health R&D at work in Rhode Island

Rhode Island Hospital’s Center for International Health Research (CIHR) is working on solutions to two of the world’s two most devastating parasitic diseases. Of all parasitic infections, malaria is the leading killer. Efforts at CIHR have yielded three vaccine candidates in the development pipeline. Second only to malaria is schistosomiasis, an infection of flatworms that damages human organs and impairs development in children. While it can be treated, a vaccine is badly needed. CIHR and partners have developed a vaccine candidate that works in mice and is showing promise in water buffalo, a major transmitter.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: NIAID/NIH